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ABSTRACT Johne’s disease, a chronic gastrointestinal inflammatory disease caused
by Mycobacterium avium subspecies paratuberculosis, is endemic in dairy cattle and
other ruminants worldwide and remains a challenge to diagnose using traditional
serological methods. Given the close phylogenetic relationship between M. avium
subsp. paratuberculosis and the human pathogen Mycobacterium tuberculosis, here,
we applied a whole-proteome M. tuberculosis protein array to identify seroreactive
and diagnostic M. avium subsp. paratuberculosis antigens. A genome-scale pairwise
analysis of amino acid identity levels between orthologous proteins in M. avium
subsp. paratuberculosis and M. tuberculosis showed an average of 62% identity, with
more than half the orthologous proteins sharing 75% identity. Analysis of the M.
tuberculosis protein array probed with sera from M. avium subsp. paratuberculosis-
infected cattle showed antibody binding to 729 M. tuberculosis proteins, with 58% of
them having 70% identity to M. avium subsp. paratuberculosis orthologs. The re-
sults showed that only 4 of the top 40 seroreactive M. tuberculosis antigens were or-
thologs of previously reported M. avium subsp. paratuberculosis antigens, revealing
the existence of a large number of previously unrecognized candidate diagnostic an-
tigens. Enzyme-linked immunosorbent assay (ELISA) testing of 20 M. avium subsp.
paratuberculosis recombinant proteins, representing reactive and nonreactive M. tu-
berculosis orthologs, further confirmed that the M. tuberculosis array has utility as a
screening tool for identifying candidate antigens for Johne’s disease diagnostics. Ad-
ditional ELISA testing of field serum samples collected from dairy herds around the
United States revealed that MAP2942c had the strongest seroreactivity with Johne’s
disease-positive samples. Collectively, our studies have considerably expanded the
number of candidate M. avium subsp. paratuberculosis proteins with potential utility
in the next generation of rationally designed Johne’s disease diagnostic assays.
KEYWORDS antigens, Mycobacterium, protein array
Johne’s disease is a chronic intestinal disease caused by infections in animals that areexposed to Mycobacterium avium subspecies paratuberculosis early in life (1). Despite
the significant economic losses associated with Johne’s disease in dairy cattle and
sheep, progress in controlling infection has been significantly impeded by the lack of
reliable and easy to use tests for detecting early infection. Over time, this results in
infected animals shedding M. avium subsp. paratuberculosis into the environment and
transmitting disease while appearing healthy. Extant enzyme immunoassays apply
cumbersome and antiquated approaches to preparing immunodiagnostic antigens that
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comprise whole-cell M. avium subsp. paratuberculosis extracts. Thus, by diluting sensi-
tive and specific antigens buried within these complex extracts, the resulting assays
have low levels of sensitivity for the detection of animals at early stages of infection. To
address this shortcoming, we have initiated a program of protein antigen discovery
based on the complete genome sequence of M. avium subsp. paratuberculosis.
The search continues for ideal antigens that can be used in antibody-based sero-
logical tests to control many infectious diseases. Animal producers want a test that
predicts infection accurately and early, while private industry will only develop cheap,
marketable tests. The latter eliminates DNA-based tests, and thus, researchers have
focused on antibody-based tests because of lower cost. The use of purified recombi-
nant proteins as antigens that specifically detect M. avium subsp. paratuberculosis will
be among the critical diagnostic tools in Johne’s disease detection, especially in the
early, subclinical stages of disease. Our group has previously used protein arrays to
screen for seroreactive antigens during early (subclinical) and late (clinical) stages of
Johne’s disease (2). Animals appear healthy in the subclinical stage, but they shed small
numbers of bacteria in their feces intermittently, thus serving as a transmission source
for herd mates. Animals in the clinical stage show disease signs, including weight loss,
diarrhea, and consistent fecal shedding of bacteria. However, it can take several years
for clinical signs to appear, making transmission difficult to stop in herds.
The M. avium subsp. paratuberculosis protein microarray is a tool that allows
simultaneous determination of antibody responses to each spotted protein using only
a small amount of serum and provides a fast, efficient approach to identify the most
immunodominant proteins for low-cost diagnosis of Johne’s disease. Furthermore, the
immunodominant proteins identified by this approach may then be used to develop M.
avium subsp. paratuberculosis peptide-based enzyme-linked immunosorbent assays
(ELISAs) that identify infected animals in both clinical and subclinical stages of disease
with high sensitivity and specificity. M. avium subsp. paratuberculosis protein arrays
were previously constructed from a collection of greater than 600 expressed and
purified M. avium subsp. paratuberculosis recombinant proteins (3). Early antigens were
identified using an experimental infection model to track the developing humoral
immune response in calves. Three antigens were identified for which antibodies were
detected in calves by 70 days postinfection (4). Antigens during the later stages of
Johne’s disease were also identified in naturally infected cattle (2). However, these
antigens are only the best of the subproteome represented on the protein array. The
question that remains is, are they the best in the entire proteome?
Even if all of the recombinant M. avium subsp. paratuberculosis proteins that are
currently available were spotted and analyzed on protein arrays, they would still
comprise less than 20% of the predicted M. avium subsp. paratuberculosis proteome
(n  4,350), demonstrating that a large fraction of potential antigen candidates have
yet to be screened. Given the time and costs associated with cloning, expressing, and
purifying additional proteins from M. avium subsp. paratuberculosis, we explored the
possibility of leveraging the availability of the whole-proteome microarray from Myco-
bacterium tuberculosis to screen for antigens useful in Johne’s disease diagnostics. M.
tuberculosis is the causative agent of human tuberculosis (TB) and is a related pathogen
belonging to the same genus as M. avium subsp. paratuberculosis. The M. tuberculosis
protein array has over 4,000 proteins spotted, which covers 99% of the M. tuberculosis
proteome (5). This novel approach is the most ambitious unbiased screen of antigens
ever undertaken for Johne’s disease.
An M. tuberculosis proteome array was constructed and used previously to deter-
mine changes in the humoral immune response in patients with TB (5). Moreover, the
array has been successfully applied to biomarker identification of active M. tuberculosis
infection in a global collection of human serum and plasma samples (5). The principal
finding was the identification of the immunoproteome, a set of antigens comprising
10% of the M. tuberculosis proteome that was highly reactive in M. tuberculosis-exposed
individuals. Systems immunology analysis yielded a smaller subset of antigens associ-
ated with active M. tuberculosis infections with primarily extracellular secretory func-
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tions. Diagnostic targets were further downselected after integrated analysis of humans
and experimentally infected cynomolgus macaques (5). Collectively, these data led us
to examine the utility of the M. tuberculosis protein array for Johne’s disease antibody
screening.
RESULTS
Genome comparison of M. avium complex and M. tuberculosis complex strains.
The M. avium complex (MAC) consists of eight species, including M. avium (6). Within
the M. avium species are four subspecies, M. avium subsp. hominissuis, M. avium subsp.
avium, M. avium subsp. silvaticum, and M. avium subsp. paratuberculosis. All four
subspecies are virtually identical at the genomic level (7, 8). Likewise, species within the
M. tuberculosis complex are all highly similar based on genomic and proteomic com-
parisons (9). However, these two mycobacterial complexes are more distantly related to
each other and are easily distinguishable. Thus, before investing in a strategy to
leverage the M. tuberculosis protein array for Johne’s disease studies, a genome scale
comparative pairwise analysis of amino acid identities between orthologous MAC and
M. tuberculosis complex proteins was performed. Analysis of Mycobacterium bovis and
M. tuberculosis species from the M. tuberculosis complex showed a biphasic histogram
with an average of 62% identity (range, 19% to 100%) among the protein-encoding
genes with M. avium subsp. paratuberculosis strain K-10, and more than half of the
orthologous proteins shared greater than 75% identity (Fig. 1), whereas the majority of
coding DNA sequences (CDSs) from the MAP4 strain were at 100% identity and M.
avium subsp. hominissuis strain 104 was at 95% percent identity or greater (Fig. 1). A
complete list of percentages of identity of CDSs for sequenced mycobacterial
FIG 1 Distribution of pairwise comparisons of M. avium subsp. paratuberculosis strain K-10 with the mycobacterial
species indicated on each graph. The histogram bars represent the frequency of CDS orthologs at a given percent
identity.
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genomes, using the MAP4 genome (10) as a reference, is presented in Table S1 in
the supplemental material. Further bioinformatics analyses confirmed that the M.
tuberculosis protein array contained more than 800 orthologs of M. avium subsp.
paratuberculosis proteins that have been previously expressed (3). An additional 1,898
M. tuberculosis proteins with 60% identity to M. avium subsp. paratuberculosis or-
thologs are present on the M. tuberculosis array but are not among the M. avium subsp.
paratuberculosis proteins that have been previously analyzed on a protein array (2, 4).
Collectively, these data strengthened the hypothesis that the M. tuberculosis protein
array might serve as a useful tool for screening over 1,800 additional candidate
antigens for Johne’s disease detection.
Protein array analysis of Johne’s disease serum samples. To directly test the
applicability of the M. tuberculosis array, 9 serum samples from cows with Johne’s
disease (6 clinical and 3 subclinical) and 3 serum samples from healthy control cows
were probed using the M. tuberculosis whole-proteome array. For comparison, an M.
avium subsp. paratuberculosis subproteomic array was also exposed to a subset of these
serum samples. The log2-transformed signal intensities of both the M. tuberculosis and
M. avium subsp. paratuberculosis arrays are shown as box and whisker plots in Fig. 2.
The raw and normalized signal intensities of the M. tuberculosis protein array are shown
in Fig. S1 in the supplemental material. The results revealed a total of 729 M. tubercu-
losis antigens that were reactive to at least one of the serum samples from cows with
Johne’s disease and had a mean intensity greater than 10 (see Table S2 in the
FIG 2 Box plots showing the overall distribution of antibody responses to M. tuberculosis and M. avium
subsp. paratuberculosis proteins. Log2-transformed signal intensities for each animal are shown in the
box plots for M. tuberculosis proteins (A) and M. avium subsp. paratuberculosis proteins (B). The black
horizontal bars, boxes, whiskers, and dots indicate the medians, ranges, 1.5 times the interquartile
ranges, and outliers, respectively. The boxes are colored based on the health status of the animals.
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supplemental material), 552 of which had an M. avium subsp. paratuberculosis ortholog
with identity above 70%, suggesting that this approach has identified hundreds of new
seroreactive M. avium subsp. paratuberculosis orthologs as potential antigen candidates
for future analysis. The top 30 M. tuberculosis proteins showing differential antibody
responses between cows in clinical and subclinical stages of disease are shown in Fig.
3A with additional information about each protein listed in Table S3 in the supple-
mental material. While most antigens had stronger antibody responses in cows in the
clinical stage of disease, four of the proteins showed significantly greater reactivity with
antibodies from animals in the subclinical stage of disease, suggesting potential early
detection antigens (Fig. 3A). Three of these proteins are annotated as hypothetical
proteins (Rv1045, Rv2184c, and Rv2315c), while Rv2162c is a PE-PGRS family protein
(11). Collectively, antibody reactivity is stronger for animals in the clinical stage of
disease than for animals in the subclinical stage of disease (Fig. 3B), and correlation of
antibody responses is strong overall, but the four proteins mentioned above (Rv1045,
Rv2315c, Rv2184c, and Rv2162c) lacked correlated responses, which may be indicative
of unique diagnostic markers (Fig. 3C).
FIG 3 M. tuberculosis proteins showing differential antibody reactivity by disease state. (A) Differences among the top 30 antigens between cows in the clinical
and subclinical stages of disease ordered from left (lowest P value) to right (highest P value, based on Student’s t test). See Table S3 in the supplemental material
for confidence intervals, P values, and adjusted P values. The bars represent the means of log2-transformed data, and the error bars represent 95% confidence
intervals. The arrows mark candidate antigens that are higher in animals in the subclinical stage of disease. (B) Heat map of the log2-transformed signals for
the top 30 antigens ordered by subclinical and clinical groups. Serum sample numbers are along the bottom, and genes are stacked in the same order as in
panel A. (C) Hierarchical clustering of the correlations between antigen reactivities. Red shows highly correlated responses, and green is uncorrelated responses,
which may highlight diagnostic markers.
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Several M. tuberculosis proteins that showed the strongest antibody reactivity with
Johne’s disease serum were also orthologous to known M. avium subsp. paratubercu-
losis antigens. For example, the strongest antibody response among cows with clinical
Johne’s disease was that of Rv1860, a proline-rich secreted protein showing a mean
signal intensity of 15.3 (see Table S2 in the supplemental material). The M. avium subsp.
paratuberculosis ortholog of this protein is MAP1569, which has been observed as a
strong antigen in multiple serological screening approaches (12–15). The second
strongest antigen among the cows in the clinical stage of disease was Rv2878c, which
is homologous to MAP2942c, another known antigen in M. avium subsp. paratubercu-
losis (16). Other published M. avium subsp. paratuberculosis antigens identified as
orthologs in Table S2 are MAP0210c (16), MAP0900 (2), and MAP2121c (17). However,
M. avium subsp. paratuberculosis orthologs for most of the M. tuberculosis antigens
identified in this study have not been described in the literature, suggesting they are
new candidate diagnostic antigens for Johne’s disease. Finally, 6 of the top 10 proteins
identified from the clinical disease stage were also ranked among the top 10 in the
subclinical disease stage (see Table S2), suggesting that these antigens may be de-
tected throughout the progression of this chronic disease.
The top 20 proteins with the highest infected-to-negative ratios on the M. avium
subsp. paratuberculosis partial protein array are shown in Table 1. A 6.40 clinical-to-
negative ratio was observed for MAP0856c, the gene for which is present on a genomic
island unique to M. avium subsp. paratuberculosis (18, 19), making it a particularly
interesting diagnostic candidate. The strongest ratio overall is 14.39 from MAP2121c, a
membrane protein that has been suggested as an antigen in the past (17, 20, 21) and
whose ortholog (Rv3347c) was ranked 33rd on the M. tuberculosis array (see Table S2
in the supplemental material). Other known M. avium subsp. paratuberculosis antigens
that appear among the top 10 clinical-to-negative ratios in Table 1 are MAP2942c (16)
and MAP1272c (22). The top 20 M. tuberculosis proteins with the highest ratios are listed
in Table S4 in the supplemental material.
TABLE 1 M. avium subsp. paratuberculosis proteins with the highest infection-to-control ratios
aRatio of average intensities of sera from cows in the subclinical stage of disease to the average intensity of sera from negative cows. Green
highlighting shows antigens with stronger subclinical antibody responses than clinical antibody responses.
bRatio of average intensities of sera from cows in the clinical stage of disease to the average intensity of sera from negative cows. Yellow
highlighting shows antigens with stronger clinical antibody responses than subclinical antibody responses.
cCy5–anti-MBP used to determine spot intensities/local correction of signal.
dNA, no ortholog in M. tuberculosis (Mtb).
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Correlation of M. avium subsp. paratuberculosis and M. tuberculosis proteins.
Correlation between the seroreactivity of antigens on the M. avium subsp. paratuber-
culosis protein array and orthologs on the M. tuberculosis array was next examined. By
taking the log2-transformed data, Pearson’s rho was 0.25 among all unique matches,
suggesting poor correlation (Fig. 4A). However, correlation among the top antigens
identified on the M. avium subsp. paratuberculosis and M. tuberculosis arrays was
stronger, with a value of 0.41 and good clustering even among proteins that had
relatively low levels of identity (Fig. 4B). Although preliminary, these data suggest that
M. tuberculosis orthologs on the M. tuberculosis arrays react to sera from M. avium
subsp. paratuberculosis-infected cows in a manner similar to what is observed with the
purified proteins spotted on the M. avium subsp. paratuberculosis array.
The distribution of reactivity for the top M. avium subsp. paratuberculosis antigens
listed in Table 1, along with the corresponding M. tuberculosis proteins, was examined
at the antigen level, along with how they correlated among disease statuses (Fig. 5).
Representative subplots are highlighted and show antigens that display good serore-
active correlation with both M. avium subsp. paratuberculosis and M. tuberculosis
proteins (Fig. 5, red boxes), as well as examples where the M. avium subsp. paratuber-
culosis antigen was a better predictor for clinical disease (Fig. 5; blue box). Those that
displayed good correlation also had high amino acid identity. For example, the M.
avium subsp. paratuberculosis protein MAP4264 was 97% identical to Rv3418c in M.
tuberculosis (Fig. 5).
Next, the distribution of reactivity for the antigens listed in Table 1 at the individual
animal level from the M. avium subsp. paratuberculosis array and their correlation with
FIG 4 Correlation between M. avium subsp. paratuberculosis (Map) and M. tuberculosis (Mtb) proteins. (A)
All orthologous genes. (B) The top antigens. Pearson’s correlation is indicated in each plot.
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the M. tuberculosis array were examined (Fig. 6). The results show, on average, good
correlation between the two arrays for each individual animal, as indicated by positive
slopes. However, two animals (53 and 2444) showed poor correlation, with slopes near
zero (Fig. 6). Collectively, these results suggest that the M. tuberculosis arrays will
provide a mechanism for the triage of M. avium subsp. paratuberculosis orthologs,
especially those with high identity but that are not seroreactive with sera from infected
animals or those that appear to be equally reactive with negative sera and infected
cows, representing targets that can be excluded from the list that may be predictive
from an M. avium subsp. paratuberculosis diagnostic assay development standpoint.
FIG 5 Correlation of seroreactive M. avium subsp. paratuberculosis antigens with M. tuberculosis proteins. The lattice plots show
log2-transformed data for M. avium subsp. paratuberculosis antibody responses (y axis) versus M. tuberculosis antibody responses (x
axis). Each subplot represents one of the top reactive M. avium subsp. paratuberculosis antigens (from Table 1) with the corresponding
orthologous M. tuberculosis antigen. Individual subjects are plotted for each antigen combination and color coded by clinical group.
A line of best fit is drawn for each subplot. The plots boxed in red indicate good seroreactive correlation with both M. avium subsp.
paratuberculosis and M. tuberculosis proteins. The plot boxed in blue indicates where M. avium subsp. paratuberculosis antigen was the
best predictor of Johne’s disease. MAP2121c is missing because there is no M. tuberculosis ortholog for the gene.
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Reactivity of M. avium subsp. paratuberculosis orthologs by ELISA. To test the
ability of the M. tuberculosis protein array to discriminate and rank strong antigens for
Johne’s disease antibody tests, 10 M. avium subsp. paratuberculosis recombinant pro-
tein orthologs corresponding to M. tuberculosis reactive proteins (see Table S2 in the
supplemental material) were selected, along with 10 recombinant protein orthologs
corresponding to low-reactive or nonreactive M. tuberculosis proteins (not listed in
Table S2). ELISAs with the same serum samples from the protein array study were used
to evaluate these 20 M. avium subsp. paratuberculosis proteins. MAP2942c was clearly
the strongest antigen among the proteins, with an average optical density (OD) reading
of 1.3 (Fig. 7A). This was also the only recombinant protein that demonstrated higher
reactivity than the whole-cell extract (Fig. 7A, K-10 sonicate). The M. tuberculosis
ortholog for the protein is Rv2878c, which ranked second among all the antigens tested
with sera from cows with clinical disease (Table S2).
The same 20 recombinant proteins were further tested using a set of well-
characterized serum samples from dairy cows around the United States. The MAP2942c
protein was once again the strongest antigen in this serum set. Comparing M. avium
subsp. paratuberculosis orthologs of the M. tuberculosis reactive and nonreactive pro-
teins showed significance (analysis of variance [ANOVA]; P  0.05) for both the positive
and negative serum repository samples (Fig. 7B). The mean sample-to-positive (S/P)
ratios were significantly higher (P  0.05) among the reactive M. avium subsp. para-
tuberculosis orthologs in the clinical and positive serum groups as measured by ELISA
(Fig. 8). Collectively, these data demonstrate that M. avium subsp. paratuberculosis
orthologs of the antigenic M. tuberculosis proteins are able to distinguish M. avium
subsp. paratuberculosis-infected cows from healthy cows.
FIG 6 Correlation of the top seroreactive M. avium subsp. paratuberculosis antigens with M. tuberculosis proteins analyzed by
individual cow. The lattice plots show log2-transformed data for M. avium subsp. paratuberculosis antibody responses (y axis)
against antibody responses to M. tuberculosis proteins (x axis). Each subplot represents the responses from one study cow, and
the dots represent the top reactive M. avium subsp. paratuberculosis antigens with the corresponding orthologous M.
tuberculosis antigens. Individual subjects are plotted for each antigen combination and color coded by clinical group. A line
of best fit is drawn for each subplot. MAP2121c was not included because there is no M. tuberculosis ortholog for the gene.
Johne’s Disease Antigen Discovery Clinical and Vaccine Immunology
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FIG 7 The humoral immune response against M. avium subsp. paratuberculosis recombinant proteins
confirms strong antigens identified from the M. tuberculosis array. Serum immunoglobin levels from
healthy and Johne’s disease cattle were analyzed by ELISA. Shown are the mean optical density values
for each protein against labeled serum samples. The M. avium subsp. paratuberculosis orthologs to
reactive M. tuberculosis proteins (from Table S2 in the supplemental material) are grouped on the left,
and orthologs to nonreactive M. tuberculosis proteins (not listed in Table S2) are grouped on the right.
The error bars represent the standard errors of the mean (SEM). (A) ELISA analysis was performed using
the same serum set as in the M. tuberculosis array study (Table 2). (B) An expanded serum set from
well-characterized dairy herds around the United States was used to further test the same recombinant
protein set (see Table S5 in the supplemental material). A total of 30 negative and 42 positive serum
samples were analyzed. The results are shown as means and SEM and were compared using analysis of
variance (ANOVA) for the 10 reactive versus 10 nonreactive M. avium subsp. paratuberculosis orthologs
for the positive and negative repository serum samples.
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DISCUSSION
Although M. avium subsp. paratuberculosis and M. tuberculosis are related mycobac-
terial species, belonging to their own complexes within the genus, the results of our
investigations suggest there is sufficient antigenic cross-reactivity to leverage the M.
tuberculosis array for Johne’s disease studies. By using the M. tuberculosis protein array
to test sera from cows with Johne’s disease, known M. avium subsp. paratuberculosis
antigens were confirmed and hundreds of new potential antigens were identified. This
study may represent the largest, unbiased screen of antigens ever undertaken for
Johne’s disease. Furthermore, the screen, combined with a large collection of recom-
binant proteins, makes it possible to construct a diagnostic platform that could range
from ELISA to miniature lateral-flow-based tests.
The results of this study have the side benefit of documenting a majority of the M.
bovis proteins that cross-react with M. avium subsp. paratuberculosis, since M. bovis is
so closely related to M. tuberculosis. This is important, because M. bovis is also a
pathogen of cattle that has important regulatory consequences (23–25), and vaccina-
tion efforts against either pathogen ideally should not interfere with diagnostic tests for
the other (26, 27). The data obtained in this study make it possible to systematically
determine cross-reactive antigens, as well as antigens that may distinguish each
pathogen. Armed with this new information, vaccine and diagnostic strategies for
either disease are better informed.
An important component of this study is the assembly of well-characterized serum
samples to enable identification of potent antigens for early and late diagnosis of
Johne’s disease. Sera were obtained from cows, along with longitudinal clinical infor-
mation so that they could be stratified by the various stages of Johne’s disease.
Although the repository serum samples could not be included in the M. tuberculosis
array study due to costs associated with printing and processing, these additional,
well-characterized sera enabled further refinement of the best antigens in the ELISA
study.
Through this approach, antigens were identified in both clinical and subclinical
groups in comparison with the ratio of intensities to those of the negative-control
FIG 8 Distribution of reactive and nonreactive M. avium subsp. paratuberculosis othologous proteins with
Johne’s disease-positive and -negative serum samples. The results are expressed as the sample-to-
positive ratio, where 0.2 was considered positive. The circles represent M. avium subsp. paratuberculosis
recombinant proteins. The horizontal bars represent the means. The cutoff value of 0.2 is indicated by
the dashed horizontal line.
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group. As expected, different patterns of serum antibody responses were observed for
cattle in clinical and subclinical stages of disease, with overall stronger responses noted
for cows in the clinical stage of disease. These results corroborate the paradigm of a
progressive increase in antibody response to M. avium subsp. paratuberculosis infection
as animals transition to more advanced stages of disease (28). Among the top 30 M.
tuberculosis antigens, ranked by P value, only 4 showed stronger antibody reactivity in
cows in the subclinical stage of disease. Notably, three of these antigens are annotated
as hypothetical proteins, suggesting that proteins that are antigenic in the subclinical
stage not only are rare but also not well characterized.
From observed differences between the two disease stages, a dynamic antibody
response to some proteins detected during subclinical Johne’s disease disappears
during the clinical stage, and the immunodominant antigens recognized by clinical sera
may not be recognized by subclinical-stage antibody responses. The hypothesis still
needs to be tested on an expanded set of samples from large-scale serum collections
that have recently been established for Johne’s disease studies. Data obtained from the
current study indicated these expanded studies are feasible and hence will be under-
taken.
According to one study describing antibody responses to the M. tuberculosis pro-
teome, 484 out of 4,099 M. tuberculosis proteins were recognized as antigenic by sera
from 240 TB patients (5), and we estimate that the M. avium subsp. paratuberculosis
proteome will have a similar number when tested with sera from Johne’s disease cattle.
Using these 484 M. tuberculosis proteins, we searched the M. avium subsp. paratuber-
culosis genome and found 361 orthologs, accounting for 74.6% of the potential M.
avium subsp. paratuberculosis antigens identified in the M. tuberculosis study. About
70% of these orthologs are not present on the M. avium subsp. paratuberculosis array
but will be included in a second-generation M. avium subsp. paratuberculosis protein
array. Bioinformatics analysis could then be used to compare epitopes and further
narrow the number of M. avium subsp. paratuberculosis proteins missing from a
whole-immunoproteome analysis.
We hypothesized that the most immunodominant proteins would be identified by
comparison between infected cattle and negative controls, as was done previously
using the M. tuberculosis microarray, where 13 proteins were identified as associated
with active TB (5). A major challenge with the current technology is to accurately
classify M. avium subsp. paratuberculosis-infected animals in different disease statuses,
particularly true-negative animals. However, another group has developed a Bayesian
methodology (29, 30) that allows us to estimate the sensitivity and specificity of a new
test even if we do not know the gold standard. This technique has been applied to the
development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi
in horses (31), and it will be employed in future studies with a larger set of Johne’s
disease cows.
Antibody screening with M. tuberculosis microarrays has identified new antigenic
proteins that are not in our collection of M. avium subsp. paratuberculosis recombinant
proteins. However, we realize that the proteins identified with an M. tuberculosis
microarray may not all be good candidates because the high identity of amino acid
sequences may contribute to cross-reactivity. Likewise, nonreactive proteins on the M.
tuberculosis microarray may not be indicative of nonreactivity in M. avium subsp.
paratuberculosis orthologs. Whereas negative responses may represent true negatives
in corresponding M. avium subsp. paratuberculosis orthologs (which will be a majority
of cases), sera may not recognize M. tuberculosis proteins, not because the correspond-
ing orthologs in M. avium subsp. paratuberculosis are not immunodominant, but
because the two orthologs are too different at the amino acid level.
Despite this, proteins showing the highest intensity were readily identified. The
most prominent protein from the ELISA study was MAP2942c, termed a Mpt53 secreted
antigen, which has been annotated as a disulfide oxidoreductase and was previously
identified by screening an expression library with sera from a cow in the clinical stage
of disease (16). In addition, the gene encoding this protein showed increased tran-
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scription in the presence of iron (32) and the rhodamine agent D157070 (33).
MAP2942c had the second highest intensity in clinical disease but was among the
weakest reactors in animals in the subclinical stage of disease, based on the M.
tuberculosis array. Likewise, MAP1569, another secreted antigen, was strongest during
clinical disease but 145th during subclinical disease (see Table S2 in the supplemental
material). The protein has been shown to activate dendritic cells and stimulate gamma
interferon (IFN-) production (34). Membrane proteins, fatty acid-coenzyme A (CoA)
synthase, and cytochrome c oxidase are among the strongest reactors during subclin-
ical disease.
The analysis showed that 1,916 M. tuberculosis proteins had at least 75% amino acid
identity to M. avium subsp. paratuberculosis; however, there are 1,805 M. avium subsp.
paratuberculosis proteins with identities to M. tuberculosis proteins below 60%. Even
though 327 of these low-identity proteins are already represented on an existing M.
avium subsp. paratuberculosis array (unpublished data), the remainder represent pro-
teins that are not likely amenable to analysis by using only the M. tuberculosis array.
Nonetheless, the results suggest that the M. tuberculosis protein microarray can be
successfully applied to M. avium subsp. paratuberculosis antibody screening, since it will
add greatly to the number of testable candidate antigens. To overcome these limita-
tions and until whole-proteome M. avium subsp. paratuberculosis arrays become avail-
able, future studies will need to consider applying sophisticated bioinformatics and
statistical analysis tools to analyze the M. avium subsp. paratuberculosis orthologs of all
positive and negative spots to make a meaningful determination on selection of M.
avium subsp. paratuberculosis protein candidates to pursue in antigen-based diagnostic
assays.
MATERIALS AND METHODS
Comparative genome analysis. The genome sequence of M. avium subsp. paratuberculosis strain
K-10, a bovine isolate from a Wisconsin dairy herd, was compared to those of M. avium subspecies
hominissuis strain 104, M. bovis AF2122/97, and M. tuberculosis H37Rv. M. avium subsp. paratuberculosis
strain MAP4, a human isolate (10), was also used in these analyses. The number of amino acid matches
was determined by pairwise analysis for all CDSs in each genome and plotted as percent identity on a
histogram.
M. tuberculosis and M. avium subsp. paratuberculosis protein array content and spotting.
Antigen Discovery, Inc. (ADI), Irvine, CA, has developed protein microarrays for antibody screening of M.
tuberculosis, Brucella, and malaria infections (5, 35, 36), as well as other prominent diseases. Therefore, the
M. tuberculosis array was fabricated by ADI as previously described (5, 37). Briefly, using M. tuberculosis
H37Rv genomic DNA as a template, all the open reading frames were amplified using custom PCR
primers. Genes greater than 3 kb in length were amplified as multiple overlapping fragments. PCR
products were cloned into a linearized T7 vector, pXI, using in vivo recombination cloning. Using
individually purified plasmids, M. tuberculosis proteins were expressed in an Escherichia coli-based in vitro
transcription and translation (IVTT) system (5 Prime, Gaithersburg, MD). The resulting IVTT reactions were
printed as single spots without further purification on custom 3-pad nitrocellulose-coated Avid slides
(Grace Bio-Labs, Bend, OR) using an OmniGrid Accent microarray printer (Digilabs, Inc., Marlborough, MA)
in 4-by-4 subarray format, with each subarray comprising 18 by 18 spots. The total number of M.
tuberculosis proteins spotted was 3,963, representing 3,864 genes (3,722 genes in the current NCBI gene
set and 142 pseudogenes from prior gene sets). Among them, 48 genes of 3 kb were fragmented into
a total of 133 segments. Each subarray included negative-control spots carrying IVTT reaction mixtures
without DNA templates, purified protein spots of previously identified M. tuberculosis biomarkers, and
positive-control spots for hybridization.
For the M. avium subsp. paratuberculosis array, 108 purified M. avium subsp. paratuberculosis K-10
recombinant proteins were selected (shown in red in Table S1 in the supplemental material) from a
recombinant protein collection (3) based on the available quantity and identity to M. tuberculosis
orthologs. In addition, 33 control spots were included for duplicate printing onto SuperEpoxy 2 glass
slides (ArrayIt, Sunnyvale, CA) using an OmniGrid 100 microarray printer. The control spots included
unconjugated bovine IgG (serially diluted) and mouse IgG for secondary-antibody binding. Additional
controls included defined peptides, such as maltose binding protein (MBP) and cell extracts from M.
avium subsp. avium, M. avium subsp. hominissuis, Mycobacterium intracellulare, Mycobacterium smegma-
tis, and Mycobacterium scrofulaceum. The negative controls included rabbit IgG, phosphate-buffered
saline (PBS), and array-printing buffer. All M. avium subsp. paratuberculosis recombinant proteins were
expressed as MBP fusions and affinity purified as described previously (38). Epoxy-activated slides were
used, since they enable high-density printing and strong protein attachment via covalent cross-linking
and high-resolution detection (39). Proteins were spotted at concentrations of 0.10 to 0.20 g/l. To
determine maximum spot intensities and local background correction, M. avium subsp. paratuberculosis
arrays were probed with monoclonal antibodies to the maltose binding protein tag. The amounts of
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protein spotted varied slightly, and this was taken into account in our analysis. All protein array slides
were stored for no more than 3 days in a desiccator cabinet at 4°C until they were ready for probing with
bovine serum samples.
Bovine serum samples. Serum samples used on the M. tuberculosis protein arrays were from
Holstein cows, including six in the clinical stage of disease and three in the subclinical stage, along with
three healthy control cows (Table 2). The same set of serum samples, with the exception of 786 and 789,
was also used on the M. avium subsp. paratuberculosis protein arrays. All of these cows were housed at
the USDA National Animal Disease Center in Ames, IA, and have an approved IACUC protocol. Further-
more, all the cows with Johne’s disease acquired the infection naturally. All the cows have documented
health histories and are tested quarterly by ELISA, IFN- response, and fecal culture. Table 2 shows the
results of these tests at the time the bleed was taken for this study. Control cows were defined as Johne’s
disease free by negative serum ELISA (IDEXX, Westbrook, ME), IFN- (Bovigam; ThermoFisher Scientific,
Waltham, MA), and fecal PCR tests. Animals in the clinical stage of disease showed Johne’s disease
symptoms, which included shedding bacteria in the feces, and a positive serum ELISA result using an M.
avium subsp. paratuberculosis antibody test kit (IDEXX). The subclinical stage of disease is not as clearly
defined, but animals in this stage are typically IFN- positive and may be intermittently shedding low
numbers of bacteria in their feces. All animals were skin test negative for bovine TB.
While the same serum samples were also used in the ELISA validation experiment, an additional 73
well-characterized bovine serum field samples from the Johne’s Disease Integrated Program Repository
were also included in this experiment (see Table S5 in the supplemental material). The repository samples
were classified into two groups based on three commercial ELISAs, as well as fecal culture and fecal PCR
(Table S5). The positive group consisted of 42 samples that were fecal culture positive and ELISA positive
and the negative group consisted of 30 samples from negative low-exposure cows.
Probing protein microarrays. Prior to incubation with serum, the M. tuberculosis and M. avium
subsp. paratuberculosis arrays were rehydrated and blocked for 30 min using protein array blocking
buffer (10485356; Maine Manufacturing, Sanford, ME) at room temperature. Serum/plasma samples were
diluted 1:200 in blocking buffer and incubated on arrays at 4°C overnight with gentle agitation. The
arrays were washed 3 times in wash buffer (Tris-buffered saline [TBS] with 0.05% Tween 20). Bound IgG
antibodies were detected with either a biotinylated anti-bovine secondary antibody (Jackson Immu-
noResearch, West Grove, PA), followed by incubation with SureLight P-3 fluorochrome conjugated to
streptavidin (Columbia Biosciences, Columbia, NY) for M. tuberculosis arrays or Cy3-conjugated anti-goat
IgG (Jackson ImmunoResearch, West Grove, PA) for M. avium subsp. paratuberculosis arrays. The M. avium
subsp. paratuberculosis array consisted of MBP-tagged recombinant proteins; thus, Cy5–anti-MBP was
used to determine spotting efficiencies. After three washes to remove unbound detection antibodies, the
slides were dried and scanned in a GenePix 4300A microarray scanner (Molecular Devices, San Diego, CA)
for M. tuberculosis arrays or a GenePix 4000B for M. avium subsp. paratuberculosis arrays. Fluorescence
intensity values for each spot were quantified using a GenePix 6.0 (Molecular Devices, Sunnyvale, CA)
utilizing local background subtraction for each spot, and the data were exported in comma-separated-
value (CSV) format. Each spot on the array is comprised of several hundred pixels. The raw values from
array scans are median intensities of all the pixels in the printed spots after background subtraction for
each protein or negative control.
Recombinant M. avium subsp. paratuberculosis antigen ELISA. Polysorb plates (Nunc; 96 well)
were coated with 50 l/well of 1 g/ml recombinant M. avium subsp. paratuberculosis protein or
MBP/LacZ or 5 g/ml M. avium subsp. paratuberculosis total antigen sonicate extract in carbonate-
bicarbonate buffer (0.06 M, pH 9.4). The plates were sealed and incubated overnight at 4°C and then
TABLE 2 Health status of cattle used in this study
Cow identifier Disease status
Test result
IDEXX ELISAa IFN-b
Fecal PCRc
IS900 ISMap02
781 Control 0.073 0.063/0.077 Neg Neg
782 Control 0.048 0.059/0.145 Neg Neg
785 Control 0.058 0.113/0.148 Neg Neg
53 Subclinical 0.046 0.120/0.474 Neg 27.95
651 Subclinical 0.023 0.124/0.279 Neg Neg
1062 Subclinical 0.053 0.141/1.468 Neg Neg
786 Clinical 2.94 0.044/0.084 26.28 16.62
789 Clinical 2.26 0.196/0.598 22.43 Neg
1442 Clinical 2.62 0.043/0.083 26.13 18.1
2222 Clinical 2.96 0.178/1.479 25.83 20.66
2444 Clinical 3.07 0.089/0.124 30.05 20.64
2491 Clinical 3.26 0.088/0.103 33.74 19.4
aA negative ELISA result is defined as less than 0.1.
bValues are reported as no stimulation/antigen stimulation. A negative IFN- test result is anything less than
0.11.
cA negative (Neg) fecal PCR result is a threshold cycle (CT) value higher than 35. IS900 has 17 copies per
genome, while ISMap02 has 6 copies per genome.
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washed three times with 0.01 M PBS, pH 7.2, containing 0.05% Tween 20 (PBS-T) (Sigma-Aldrich, St. Louis,
MO, USA). The wells were blocked by adding 200 l/well of PBS-T containing 1% bovine serum albumin
(PBS-T–BSA) and incubating at room temperature for 1 h before washing the plate three times with
PBS-T. Serum samples, diluted 1:250 in PBS-T–BSA, were added to duplicate wells (100 l/well) and
incubated at room temperature for 1 h before washing three times with PBS-T. Then, 100 l/well of
anti-goat IgG peroxidase conjugate (Vector Laboratories, Burlingame, CA, USA) diluted 1:20,000 in
PBS-T–BSA was added to all the wells and incubated at room temperature for 1 h before the plates were
again washed three times with PBS-T. Finally, 100 l/well of tetramethylbenzidine (TMB) SureBlue
solution (KPL, Gaithersburg, MD, USA) was added, and the reaction was allowed to progress for 10 to 15
min at room temperature with no light before the reaction was stopped with 100 l/well of TMB stop
solution (KPL). Spectrophotometric reading of all the wells was performed at 450 nm using a SpectraMax
340PC384 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Readings were analyzed by the S/P
ratio, which was calculated as follows: S/P ratio  (sample OD  negative-control OD)/(positive-control
OD  negative-control OD). Samples were considered positive if the S/P ratio was greater than 0.20.
Data analysis. The intensity data files in CSV format were read in, processed, and analyzed using an
automated data analysis pipeline developed at ADI (Irvine, CA) that is implemented in R (http://www.r
-project.org). Spot intensity measurements were converted into a single data matrix of intensities with
the local background subtracted. For each sample, quality checks were performed for possible missing
spots, contamination, and unusual background variation. The data were also inspected for the presence
of subtle systematic effects and biases (probing day, slide, pad, print order, etc.). Once the data passed
quality assurance, the final data set utilized for analysis was obtained by log2 transformation of raw
intensities for variance stabilization without further adjustment due to low, homogeneous background
levels. An antigen was classified as reactive to a given sample if antibody target signal intensity values
were at least twice the sample’s median IVTT negative control. Data were modeled using parametric
(Student’s t test) and nonparametric (Wilcoxon’s rank sum test and area under the concentration-time
curve [AUC] estimation) tests for between-group comparisons. The data were visualized using bar graphs,
box plots, and heat maps for antibody levels. Hierarchical clustering of between-group antibody
correlations was used to identify sets of antibody targets with diagnostic potential. Correlation of
antibody responses between M. avium subsp. paratuberculosis and M. tuberculosis orthologs was as-
sessed using Pearson’s correlation coefficient (rho). Qualification of means was done, with 95% confi-
dence intervals, and interquartile ranges were used for medians. P values were adjusted for the
false-discovery rate (FDR) using the Benjamini-Hochberg method, and P values of 0.05 were considered
significant (40).
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